SHTDY SINOPHARM GROUP CO
WatchlistSINOPHARM GROUP CO News
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Sinopharm Holdings (01099.HK) was reduced by 1,754 million shares by FMR LLC
Gelonghui November 16 | According to the latest equity disclosure data from the Stock Exchange, on November 10, 2023, Sinopharm Holdings (01099.HK) was reduced by 1,754 million shares by FMR LLC at an average price of HK$19.1627 per share, involving approximately HK$32.681 million. After reducing its holdings, the latest number of shares held by FMR LLC was 160,276,364 shares, and the shareholding ratio fell from 12.07% to 11.94%.
An Intrinsic Calculation For Sinopharm Group Co. Ltd. (HKG:1099) Suggests It's 26% Undervalued
Key Insights The projected fair value for Sinopharm Group is HK$26.57 based on 2 Stage Free Cash Flow to Equity Current share price of HK$19.60 suggests Sinopharm Group is potentially 26% undervalue
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
Sinopharm Group (HKG:1099) May Have Issues Allocating Its Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secon
Sinopharm Holdings (01099) announced the first three quarter results, net profit of about 6.096 billion yuan, up 4.09% year-on-year
According to the Zhitong Finance App, Sinopharm Holdings (01099) announced that in the first three quarters of 2023, total operating income was about 445.92 billion yuan, up 9.73% year on year; net profit attributable to owners of the parent company was about 6.096 billion yuan, up 4.09% year on year; basic earnings per share of 1.96 yuan.
SINOPHARM: ANNOUNCEMENT QUARTERLY FINANCIAL INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
China National Accord Medicines' Profit Slides 4% in Q3
China National Accord Medicines' (SHE:000028, SHE:200028) attributable net profit fell 3.75% year over year to 359.4 million yuan in the third quarter of 2023. Earnings per share for the July to Septe
SINOPHARM: ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2023
Sinopharm Holdings: Sinopharm's net profit for the first three quarters was about 678 million yuan, a year-on-year decrease of 11.88%
Sinopharm Holdings (01099) announced the results of Sinopharm Devices for the nine months ended September 30, 2023. The group obtained revenue of 60.222 billion yuan (RMB, same below) during the period, an increase of 10.43% over the previous year; the total comprehensive income attributable to owners of the parent company was about 678 million yuan, a decrease of 11.88% over the previous year.
SINOPHARM: ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Sinopharm Holdings: Sinopharm's net profit for the third quarter was about 478 million yuan, a year-on-year decrease of 16.1%
Sinopharm Holdings (01099) announced the results of Sinopharm Co., Ltd. (600511.SH) for the third quarter of 2023, with operating income of about 12.389 billion yuan, a year-on-year decrease of 1.17%; net profit attributable to shareholders of listed companies was about 478 million yuan, a year-on-year decrease of 16.1%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was about 480 million yuan, a year-on-year decrease of 15.36%; and basic earnings per share of 0.6332 yuan.
SINOPHARM: ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2023
Nomura: Maintaining Sinopharm Holdings' “buy” rating target price reduced to HK$33.31
Nomura released a research report saying that maintaining the “buy” rating of Sinopharm Holdings (01099) was slightly lowered by 1.9%/1.7%, 4.2% and 4% lower than market expectations, to reflect the increase in gross margin pressure brought about by volume procurement (VBP) of pharmaceuticals and medical equipment (VBP) in the second half of this year and beyond. The target price dropped from HK$36.28 to HK$33.31. The bank said it is still optimistic that the company will achieve a leading position with growth above the industry average, and believes it is betting on an alternative investment target for the growing mainland healthcare industry. It is also believed that the current anti-corruption campaign in the mainland affects countries
Nomura: Maintaining the “buy” rating of Sinopharm Holdings (01099), the target price dropped to HK$33.31
Nomura is still optimistic that Sinopharm will achieve a leading position with growth above the industry average, and believes it is an alternative investment target betting on the growing mainland healthcare industry.
Is Weakness In Sinopharm Group Co. Ltd. (HKG:1099) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Sinopharm Group (HKG:1099) has had a rough three months with its share price down 4.1%. But if you pay close attention, you might gather that its strong financials could mean that the stock could po
Sinopharm Holdings (01099.HK) will hold a board meeting on October 27 to approve the first three quarter results
GLONGHUI, Oct. 13丨Sinopharm Holdings (01099.HK) announced that the company will hold a board meeting on October 27, 2023 to consider and approve the unaudited quarterly results of the company and its subsidiaries for the nine months ended September 30, 2023.